Foamix Pharmaceuticals LTD. – Ordinary Shares (NASDAQ:FOMX) on Focus After Report of Less Shorts

The stock of Foamix Pharmaceuticals LTD. – Ordinary Shares (NASDAQ:FOMX) registered a decrease of 3.59% in short interest. FOMX’s total short interest was 1.15M shares in December as published by FINRA. Its down 3.59% from 1.20M shares, reported previously. With 171,900 shares average volume, it will take short sellers 7 days to cover their FOMX’s short positions. The short interest to Foamix Pharmaceuticals LTD. – Ordinary Shares’s float is 4.31%.

The stock decreased 4.66% or $0.2 during the last trading session, reaching $4.09. About 204,344 shares traded. Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has risen 14.42% since December 8, 2017 and is uptrending. It has underperformed by 1.20% the S&P500.

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France. The company has market cap of $222.02 million. The Company’s lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. It currently has negative earnings. The firm is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash.

More notable recent Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) news were published by: Globenewswire.com which released: “Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters – GlobeNewswire” on September 18, 2018, also Seekingalpha.com with their article: “Foamix Pharma down 9% – Seeking Alpha” published on September 18, 2018, Nasdaq.com published: “Recent Analysis Shows WPX Energy, Verizon Communications, Innovative Industrial Properties, Foamix Pharmaceuticals, O2Micro International, and Investment Technology Group Market Influences — Renewed Outlook, Key Drivers of Growth – Nasdaq” on November 13, 2018. More interesting news about Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) were released by: Globenewswire.com and their article: “Foamix Announces Appointment of Anthony Bruno to Board of Directors – GlobeNewswire” published on November 19, 2018 as well as Globenewswire.com‘s news article titled: “Foamix Announces $16 Million Investment by OrbiMed Nasdaq:FOMX – GlobeNewswire” with publication date: April 16, 2018.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.